OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded corporations. Investments are made in one of four distinct strategies: private equity funds, hedge funds, royalty funds and mutual funds.
OrbiMed's hedge fund strategy was initiated in 1993 to invest both long and short in the global healthcare sector. These funds employ an event-driven, fundamental research approach that seeks to identify mispriced securities with a pending catalyst for value realization. These funds invest worldwide, seeking the broadest possible opportunity set and reduced volatility through global diversification.
OrbiMed's public mutual fund business was launched in 1989 to invest worldwide in healthcare companies. Funds under management include the Eaton Vance Worldwide Health Sciences Fund, the Worldwide Healthcare Trust PLC, and the Biotechnology Growth Trust PLC.
Private Equity Funds
North America and Europe: OrbiMed has been an active investor in healthcare private equity since 1993. Our private equity strategy is opportunistic and balanced, with investments across all stages of development. OrbiMed is usually the lead investor in its portfolio companies and seeks an active role in creating value at our portfolio companies.
Asia: OrbiMed's Asia private equity fund is focused on opportunities in China and India across all sectors of healthcare, including healthcare services. Led by a dedicated team based in Shanghai and Mumbai, OrbiMed is able to combine the strengths of its local team with the resources of its global platform to assist companies in Asia with their growth objectives.
Israel: OrbiMed's Israel private equity fund invests in the full spectrum of Israeli life sciences innovation including pharmaceuticals, biotechnology, medical devices and diagnostics. Portfolio companies can range from seed stage to commercial growth equity. OrbiMed's dedicated local team brings a strong combination of operating, scientific and business experience to help companies develop successfully and maximize their commercial potential.
Royalty Opportunities Funds
Through this fund, OrbiMed invests in and acquires royalty streams on approved, patent-protected healthcare products. Additionally, OrbiMed provides commercial-stage public and private companies with non- or minimally-dilutive structured debt capital.
If you are an investor interested in learning more about our funds, please contact Carter Neild or Bill Price at (212) 739-6400, or send us an "email".